8月29日晚，美年大健康产业控股股份有限公司（以下简称"美年健康（002044）"，002044.SZ）发布的 2025年半年度报告显示，公司实现营业总收入41.09亿元；其中主营收入中结合AI技术手段取得的收入 为1.4亿元，较上年同期增长62.36%，主要包括心肺联筛、AI-MDT报告、肺结宁、脑睿佳、数智云胶 片、眼底AI等收入。 美年健康表示，在上半年传统淡季，受宏观环境影响，部分企业预算及到检后置，"整体订单签订、客 单价、个检市场相对稳定"，公司积极推动重点客户签单占比、到检份额提升，持续推动团检向个检的 转化与裂变。"上半年提效降本取得一定进展，公司继续基于AI与数字化，持续提升医质和服务质量， 并积极推动提效降本以及创新创收工作，更好地迎接下半年体检旺季。" 在慢病专管场景，美年健康上半年推出"AI智能肝健康管理产品"，通过超声弹性成像+生化指标+AI模 型，预测肝纤维化程度。据了解，美年健康AI慢病管理产品矩阵已初具规模，持续升级肺结宁、脑睿 佳等明星产品线，同时加强推广"AI智能血糖管理创新产品"、"中医智能体检项目"等重点AI专精特新服 务产品应用。 可以发现，近年来，美年健康通过技术创 ...

Core Viewpoint - CapsoVision is planning an IPO to raise up to $30 million to enhance its position in the non-invasive gastrointestinal diagnostics market, particularly for its CapsoCam Plus product [1]. Company Overview - CapsoVision, founded in 2006 and headquartered in Saratoga, California, focuses on non-invasive gastrointestinal diagnostic technologies and has entered multiple markets including North America, Europe, and Asia-Pacific [14]. Product Introduction - The core product, CapsoCam Plus, is a swallowable capsule endoscope designed for small intestine examinations, providing non-invasive and high-quality imaging [2]. - The product received FDA 510(k) certification in 2016 and expanded its indications to include pediatric patients aged 2 and above in 2025 [2]. Product Features - CapsoCam Plus features 360° panoramic imaging with four side cameras, significantly improving visual coverage compared to traditional forward-facing lenses [3]. - It offers wireless data storage, eliminating the need for external receiving devices, and allows for natural expulsion through bowel movements [3]. - The high-resolution images support the identification of common small intestine lesions such as ulcers and bleeding [3]. - The examination process does not require anesthesia or hospitalization, making it suitable for patients who are reluctant to undergo traditional endoscopy, especially children and the elderly [3]. Market Demand - The incidence of gastrointestinal diseases is rising globally, with approximately 20 million new cancer cases reported in 2023, including colorectal and gastric cancers [8]. - The global capsule endoscopy market was valued at approximately $537 million in 2023 and is projected to grow to between $1.02 billion and $1.6 billion by 2030, with a CAGR of 8.4%-9.6% [8]. - The Asia-Pacific region, particularly China, is the fastest-growing market, expected to achieve over 15% CAGR by 2030, with a market size potentially exceeding 3 billion RMB [8]. Competitive Landscape - The capsule endoscopy market is highly concentrated, with Medtronic leading globally, while local companies like AnHuan and Jinshan are rapidly emerging in the Chinese market [9][11]. - CapsoVision's CapsoCam Plus competes with products from Medtronic, IntroMedic, and Olympus, each offering unique features such as AI integration and remote access capabilities [9][11]. Software and Technology - The CapsoView software, launched in 2023, supports cloud-based access and data sharing, enhancing image analysis efficiency [7][10]. - The company is exploring the integration of artificial intelligence to improve diagnostic accuracy and efficiency [7][10].